AMP-activated protein kinase: An emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases

Journal of Lipid Research

Volumn 53, Issue 12, 2012, Pages 2490-2514

  Srivastava, Rai Ajit K ^a   Pinkosky, Stephen L ^a   Filippov, Sergey ^a   Hanselman, Jeffrey C ^a   Cramer, Clay T ^a   Newton, Roger S ^a  

^a Esperion Therapeutics Inc   (United States)

Author keywords

Atherosclerosis; Cholesterol; Diabetes; Drug therapy; Dyslipidemias; Fatty acid; Hepatic steatosis; Inflammation; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; APIGENIN; BERBERINE; CALCIMYCIN; CARBOHYDRATE; FETUIN A; FLAVONOID; GENISTEIN; GHRELIN; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; INSULIN; LEPTIN; LIPID; METFORMIN; NARINGENIN; PHENFORMIN; PIOGLITAZONE; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; ROSIGLITAZONE; S 17834; SULFONYLUREA; THIOCTIC ACID; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID METABOLISM; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENERGY BALANCE; ENERGY METABOLISM; ENZYME INHIBITION; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPID LIVER LEVEL; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; REVIEW; STRUCTURE ANALYSIS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASES; ENZYME ACTIVATORS; HUMANS; LIPID METABOLISM;

EID: 84869021501     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R025882     Document Type: Review

References (303)

1. Grundy, S. M. 2000. Metabolic complications of obesity. Endocrine. 13: 155-165.
2. Han, S., C. P. Liang, M. Westerterp, T. Senokuchi, C. L. Welch, Q. Wang, M. Matsumoto, D. Accili, and A. R. Tall. 2009. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice. J. Clin. Invest. 119: 1029-1041.
3. Boyd, S. T., D. M. Scott, and A. M. Pick. 2009. Pill burden in low-income patients with metabolic syndrome and diabetes. J. Pharm. Technol. 25: 297-302.
4. Srivastava, R. A., and N. Srivastava. 2004. Search for obesity drugs: targeting central and peripheral pathways. Curr. Med. Chem. Immunol. Endocr. Metab. Agents. 4: 75-90. (Pubitemid 38854959)
5. Hardie, D. G. 2004. The AMP-activated protein kinase pathway - new players upstream and downstream. J. Cell Sci. 117: 5479-5487. (Pubitemid 40012195)
6. Cheung, P. C., I. P. Salt, S. P. Davies, D. G. Hardie, and D. Carling. 2000. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem. J. 346: 659-669. (Pubitemid 30171026)
7. Birnbaum, M. J. 2005. Activating AMP-activated protein kinase without AMP. Mol. Cell. 19: 289-290. (Pubitemid 41074882)
8. Hardie, D. G. 2003. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 144: 5179-5183. (Pubitemid 37476044)
9. Beg, Z. H., D. W. Allmann, and D. M. Gibson. 1973. Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and wth protein fractions of rat liver cytosol. Biochem. Biophys. Res. Commun. 54: 1362-1369.
10. Carlson, C. A., and K. H. Kim. 1973. Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J. Biol. Chem. 248: 378-380.
11. Viollet, B., M. Foretz, B. Guigas, S. Horman, R. Dentin, L. Bertrand, L. Hue, and F. Andreelli. 2006. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J. Physiol. 574: 41-53. (Pubitemid 43905795)
12. Towler, M. C., and D. G. Hardie. 2007. AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res. 100: 328-341.
13. Kola, B. 2008. Role of AMP-activated protein kinase in the control of appetite. J. Neuroendocrinol. 20: 942-951. (Pubitemid 351859112)
14. Hardie, D. G. 2004. AMP-activated protein kinase: a master switch in glucose and lipid metabolism. Rev. Endocr. Metab. Disord. 5: 119-125. (Pubitemid 39022492)
15. Daval, M., F. Foufelle, and P. Ferre. 2006. Functions of AMP-activated protein kinase in adipose tissue. J. Physiol. 574: 55-62. (Pubitemid 43905796)
16. Hardie, D. G., and D. A. Pan. 2002. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem. Soc. Trans. 30: 1064-1070. (Pubitemid 36002407)
17. Düfer, M., K. Noack, P. Krippeit-Drews, and G. Drews. 2010. Activation of the AMP-activated protein kinase enhances glucose-stimulated insulin secretion in mouse beta-cells. Islets. 2: 156-163.
18. Hawley, S. A., M. Davison, A. Woods, S. P. Davies, R. K. Beri, D. Carling, and D. G. Hardie. 1996. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J. Biol. Chem. 271: 27879-27887. (Pubitemid 26367365)
19. Crute, B. E., K. Seefeld, J. Gamble, B. E. Kemp, and L. A. Witters. 1998. Functional domains of the alpha1 catalytic subunit of the AMP-activated protein kinase. J. Biol. Chem. 273: 35347-35354. (Pubitemid 29028244)
20. Pang, T., B. Xiong, J. Y. Li, B. Y. Qiu, G. Z. Jin, J. K. Shen, and J. Li. 2007. Conserved alpha-helix acts as autoinhibitory sequence in AMP-activated protein kinase alpha subunits. J. Biol. Chem. 282: 495-506. (Pubitemid 47076612)
21. Bendayan, M., I. Londono, B. E. Kemp, G. D. Hardie, N. Ruderman, and M. Prentki. 2009. Association of AMP-activated protein kinase subunits with glycogen particles as revealed in situ by immunoelectron microscopy. J. Histochem. Cytochem. 57: 963-971.
22. Hudson, E. R., D. A. Pan, J. James, J. M. Lucocq, S. A. Hawley, K. A. Green, O. Baba, T. Terashima, and D. G. Hardie. 2003. A novel domain in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. Curr. Biol. 13: 861-866. (Pubitemid 36573255)
23. McBride, A., S. Ghilagaber, A. Nikolaev, and D. G. Hardie. 2009. The glycogen-binding domain on the AMPK beta subunit allows the kinase to act as a glycogen sensor. Cell Metab. 9: 23-34.
24. Polekhina, G., A. Gupta, B. J. Michell, B. van Denderen, S. Murthy, S. C. Feil, I. G. Jennings, D. J. Campbell, L. A. Witters, M. W. Parker, et al. 2003. AMPK beta subunit targets metabolic stress sensing to glycogen. Curr. Biol. 13: 867-871. (Pubitemid 36573256)
25. Oakhill, J. S., Z. P. Chen, J. W. Scott, R. Steel, L. A. Castelli, N. Ling, S. L. Macaulay, and B. E. Kemp. 2010. beta-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc. Natl. Acad. Sci. USA. 107: 19237-19241.
26. Kemp, B. E. 2004. Bateman domains and adenosine derivatives form a binding contract. J. Clin. Invest. 113: 182-184. (Pubitemid 38544202)
27. Bateman, A. 1997. The structure of a domain common to archaebacteria and the homocystinuria disease protein. Trends Biochem. Sci. 22: 12-13. (Pubitemid 27056090)
28. Kemp, B. E., J. S. Oakhill, and J. W. Scott. 2007. AMPK structure and regulation from three angles. Structure. 15: 1161-1163. (Pubitemid 47539170)
29. Morrison, A., X. Yan, C. Tong, and J. Li. 2011. Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice. Am. J. Physiol. Heart Circ. Physiol. 301: H895-H902.
30. Bonen, A., X. X. Han, D. D. Habets, M. Febbraio, J. F. Glatz, and J. J. Luiken. 2007. A null mutation in skeletal muscle FAT/CD36 reveals its essential role in insulin- and AICAR-stimulated fatty acid metabolism. Am. J. Physiol. Endocrinol. Metab. 292: E1740-E1749. (Pubitemid 47084709)
31. Davies, S. P., N. R. Helps, P. T. Cohen, and D. G. Hardie. 1995. 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Lett. 377: 421-425. (Pubitemid 26027159)
32. Sanders, M. J., P. O. Grondin, B. D. Hegarty, M. A. Snowden, and D. Carling. 2007. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem. J. 403: 139-148. (Pubitemid 46569875)
33. Suter, M., U. Riek, R. Tuerk, U. Schlattner, T. Wallimann, and D. Neumann. 2006. Dissecting the role of 5′-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J. Biol. Chem. 281: 32207-32216. (Pubitemid 46036775)
34. Chen, Z. P., T. J. Stephens, S. Murthy, B. J. Canny, M. Hargreaves, L. A. Witters, B. E. Kemp, and G. K. McConell. 2003. Effect of exercise intensity on skeletal muscle AMPK signaling in humans. Diabetes. 52: 2205-2212. (Pubitemid 37059489)
35. Frederich, M., and J. A. Balschi. 2002. The relationship between AMP-activated protein kinase activity and AMP concentration in the isolated perfused rat heart. J. Biol. Chem. 277: 1928-1932. (Pubitemid 34968770)
36. Hellsten, Y., E. A. Richter, B. Kiens, and J. Bangsbo. 1999. AMP deamination and purine exchange in human skeletal muscle during and after intense exercise. J. Physiol. 520: 909-920. (Pubitemid 29533045)
37. Veech, R. L., J. W. Lawson, N. W. Cornell, and H. A. Krebs. 1979. Cytosolic phosphorylation potential. J. Biol. Chem. 254: 6538-6547.
38. Jin, X., R. Townley, and L. Shapiro. 2007. Structural insight into AMPK regulation: ADP comes into play. Structure. 15: 1285-1295. (Pubitemid 47539159)
39. Hardie, D. G., D. Carling, and S. J. Gamblin. 2011. AMP-activated protein kinase: also regulated by ADP? Trends Biochem. Sci. 36: 470-477.
40. Carling, D., F. V. Mayer, M. J. Sanders, and S. J. Gamblin. 2011. AMP-activated protein kinase: nature's energy sensor. Nat. Chem. Biol. 7: 512-518.
41. Woods, A., S. R. Johnstone, K. Dickerson, F. C. Leiper, L. G. Fryer, D. Neumann, U. Schlattner, T. Wallimann, M. Carlson, and D. Carling. 2003. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13: 2004-2008. (Pubitemid 37425212)
42. Brajenovic, M., G. Joberty, B. Kuster, T. Bouwmeester, and G. Drewes. 2004. Comprehensive proteomic analysis of human Par protein complexes reveals an interconnected protein network. J. Biol. Chem. 279: 12804-12811. (Pubitemid 38445853)
43. Boudeau, J., A. F. Baas, M. Deak, N. A. Morrice, A. Kieloch, M. Schutkowski, A. R. Prescott, H. C. Clevers, and D. R. Alessi. 2003. MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J. 22: 5102-5114. (Pubitemid 37222030)
44. Baas, A. F., J. Boudeau, G. P. Sapkota, L. Smit, R. Medema, N. A. Morrice, D. R. Alessi, and H. C. Clevers. 2003. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J. 22: 3062-3072. (Pubitemid 36758626)
45. Hawley, S. A., D. A. Pan, K. J. Mustard, L. Ross, J. Bain, A. M. Edelman, B. G. Frenguelli, and D. G. Hardie. 2005. Calmodul-independent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2: 9-19. (Pubitemid 43239821)
46. Woods, A., K. Dickerson, R. Heath, S. P. Hong, M. Momcilovic, S. R. Johnstone, M. Carlson, and D. Carling. 2005. Ca2+/calmodul-independent protein kinase kinase-beta acts upstream of AMPactivated protein kinase in mammalian cells. Cell Metab. 2: 21-33. (Pubitemid 43239822)
47. Hurley, R. L., K. A. Anderson, J. M. Franzone, B. E. Kemp, A. R. Means, and L. A. Witters. 2005. The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 280: 29060-29066. (Pubitemid 41161355)
48. Hawley, S. A., M. A. Selbert, E. G. Goldstein, A. M. Edelman, D. Carling, and D. G. Hardie. 1995. 5′-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J. Biol. Chem. 270: 27186-27191.
49. Hardie, D. G. 2011. Sensing of energy and nutrients by AMP-activated protein kinase. Am. J. Clin. Nutr. 93: 891S-896S.
50. Momcilovic, M., S. P. Hong, and M. Carlson. 2006. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem. 281: 25336-25343. (Pubitemid 44401921)
51. Munday, M. R., D. G. Campbell, D. Carling, and D. G. Hardie. 1988. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur. J. Biochem. 175: 331-338.
52. Clarke, P. R., and D. G. Hardie. 1990. Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver. EMBO J. 9: 2439-2446.
53. Muoio, D. M., K. Seefeld, L. A. Witters, and R. A. Coleman. 1999. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem. J. 338: 783-791. (Pubitemid 29140087)
54. Merrill, G. F., E. J. Kurth, D. G. Hardie, and W. W. Winder. 1997. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am. J. Physiol. 273: E1107-E1112.
55. Watt, M. J., A. G. Holmes, S. K. Pinnamaneni, A. P. Garnham, G. R. Steinberg, B. E. Kemp, and M. A. Febbraio. 2006. Regulation of HSL serine phosphorylation in skeletal muscle and adipose tissue. Am. J. Physiol. Endocrinol. Metab. 290: E500-E508. (Pubitemid 43671697)
56. Ahmadian, M., M. J. Abbott, T. Tang, C. S. Hudak, Y. Kim, M. Bruss, M. K. Hellerstein, H. Y. Lee, V. T. Samuel, G. I. Shulman, et al. 2011. Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype. Cell Metab. 13: 739-748.
57. Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, et al. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108: 1167-1174. (Pubitemid 32995375)
58. Leclerc, I., C. Lenzner, L. Gourdon, S. Vaulont, A. Kahn, and B. Viollet. 2001. Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. Diabetes. 50: 1515-1521. (Pubitemid 33639590)
59. Kawaguchi, T., K. Osatomi, H. Yamashita, T. Kabashima, and K. Uyeda. 2002. Mechanism for fatty acid "sparing" effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J. Biol. Chem. 277: 3829-3835. (Pubitemid 34968632)
60. Sakamoto, K., and G. D. Holman. 2008. Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am. J. Physiol. Endocrinol. Metab. 295: E29-E37.
61. Marsin, A. S., C. Bouzin, L. Bertrand, and L. Hue. 2002. The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase. J. Biol. Chem. 277: 30778-30783. (Pubitemid 34970775)
62. Jørgensen, S. B., J. N. Nielsen, J. B. Birk, G. S. Olsen, B. Viollet, F. Andreelli, P. Schjerling, S. Vaulont, D. G. Hardie, B. F. Hansen, et al. 2004. The alpha2-5′AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. Diabetes. 53: 3074-3081. (Pubitemid 39564481)
63. Koo, S. H., L. Flechner, L. Qi, X. Zhang, R. A. Screaton, S. Jeffries, S. Hedrick, W. Xu, F. Boussouar, P. Brindle, et al. 2005. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 437: 1109-1111.
64. Mihaylova, M. M., D. S. Vasquez, K. Ravnskjaer, P. D. Denechaud, R. T. Yu, J. G. Alvarez, M. Downes, R. M. Evans, M. Montminy, and R. J. Shaw. 2011. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell. 145: 607-621.
65. Zong, H., J. M. Ren, L. H. Young, M. Pypaert, J. Mu, M. J. Birnbaum, and G. I. Shulman. 2002. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl. Acad. Sci. USA. 99: 15983-15987. (Pubitemid 35462735)
66. Hardie, D. G. 2011. AMPK and autophagy get connected. EMBO J. 30: 634-635.
67. Gwinn, D. M., D. B. Shackelford, D. F. Egan, M. M. Mihaylova, A. Mery, D. S. Vasquez, B. E. Turk, and R. J. Shaw. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell. 30: 214-226. (Pubitemid 351626684)
68. Inoki, K., T. Zhu, and K. L. Guan. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 115: 577-590. (Pubitemid 37506046)
69. Suchankova, G., M. Tekle, A. K. Saha, N. B. Ruderman, S. D. Clarke, and T. W. Gettys. 2005. Dietary polyunsaturated fatty acids enhance hepatic AMP-activated protein kinase activity in rats. Biochem. Biophys. Res. Commun. 326: 851-858. (Pubitemid 39655997)
70. Reaven, G. M. 1995. Pathophysiology of insulin resistance in human disease. Physiol. Rev. 75: 473-486.
71. Watanabe, S., R. Yaginuma, K. Ikejima, and A. Miyazaki. 2008. Liver diseases and metabolic syndrome. J. Gastroenterol. 43: 509-518.
72. Muoio, D. M., and C. B. Newgard. 2006. Obesity-related derangements in metabolic regulation. Annu. Rev. Biochem. 75: 367-401. (Pubitemid 44118037)
73. Boizard, M., X. Le Liepvre, P. Lemarchand, F. Foufelle, P. Ferre, and I. Dugail. 1998. Obesity-related overexpression of fattyacid synthase gene in adipose tissue involves sterol regulatory element-binding protein transcription factors. J. Biol. Chem. 273: 29164-29171. (Pubitemid 28507616)
74. Srivastava, R. A., R. Jahagirdar, S. Azhar, S. Sharma, and C. L. Bisgaier. 2006. Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol. Cell. Biochem. 285: 35-50.
75. Srivastava, R. A., and S. He. 2010. Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster. Mol. Cell. Biochem. 345: 197-206.
76. Godbole, V. Y., M. L. Grundleger, and S. W. Thenen. 1980. Early development of lipogenesis in genetically obese (ob/ob) mice. Am. J. Physiol. 239: E265-E268. (Pubitemid 10008816)
77. Kaplan, M. L., and G. A. Leveille. 1981. Development of lipogenesis and insulin sensitivity in tissues of the ob/ob mouse. Am. J. Physiol. 240: E101-E107. (Pubitemid 11130365)
78. Andreelli, F., M. Foretz, C. Knauf, P. D. Cani, C. Perrin, M. A. Iglesias, B. Pillot, A. Bado, F. Tronche, G. Mithieux, et al. 2006. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology. 147: 2432-2441.
79. Foretz, M., N. Ancellin, F. Andreelli, Y. Saintillan, P. Grondin, A. Kahn, B. Thorens, S. Vaulont, and B. Viollet. 2005. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes. 54: 1331-1339. (Pubitemid 40586661)
80. Bergeron, R., S. F. Previs, G. W. Cline, P. Perret, R. R. Russell 3rd, L. H. Young, and G. I. Shulman. 2001. Effect of 5-aminoimidazole-4-carboxamide-1- beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes. 50: 1076-1082. (Pubitemid 32374538)
81. Sakamoto, K., O. Goransson, D. G. Hardie, and D. R. Alessi. 2004. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am. J. Physiol. Endocrinol. Metab. 287: E310-E317. (Pubitemid 38943898)
82. Brunmair, B., K. Staniek, F. Gras, N. Scharf, A. Althaym, R. Clara, M. Roden, E. Gnaiger, H. Nohl, W. Waldhausl, et al. 2004. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes. 53: 1052-1059. (Pubitemid 38436618)
83. Jørgensen, S. B., B. Viollet, F. Andreelli, C. Frosig, J. B. Birk, P. Schjerling, S. Vaulont, E. A. Richter, and J. F. Wojtaszewski. 2004. Knockout of the alpha2 but not alpha1 5′-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J. Biol. Chem. 279: 1070-1079. (Pubitemid 38082628)
84. Shirai, T., E. Inoue, Y. Ishimi, and J. Yamauchi. 2011. AICAR response element binding protein (AREBP), a key modulator of hepatic glucose production regulated by AMPK in vivo. Biochem. Biophys. Res. Commun. 414: 287-291.
85. Bultot, L., B. Guigas, A. Von Wilamowitz-Moellendorff, L. Maisin, D. Vertommen, N. Hussain, M. Beullens, J. J. Guinovart, M. Foretz, B. Viollet, et al. 2012. AMP-activated protein kinase phosphorylates and inactivates liver glycogen synthase. Biochem. J. 44: 193-203.
86. Carlson, C. L., and W. W. Winder. 1999. Liver AMP-activated protein kinase and acetyl-CoA carboxylase during and after exercise. J. Appl. Physiol. 86: 669-674. (Pubitemid 29075823)
87. Dentin, R., F. Benhamed, I. Hainault, V. Fauveau, F. Foufelle, J. R. Dyck, J. Girard, and C. Postic. 2006. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes. 55: 2159-2170. (Pubitemid 44743612)
88. Choi, C. S., D. B. Savage, L. Abu-Elheiga, Z. X. Liu, S. Kim, A. Kulkarni, A. Distefano, Y. J. Hwang, R. M. Reznick, R. Codella, et al. 2007. Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc. Natl. Acad. Sci. USA. 104: 16480-16485. (Pubitemid 350211044)
89. Ruderman, N., and M. Prentki. 2004. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat. Rev. Drug Discov. 3: 340-351. (Pubitemid 38499761)
90. Imai, K., K. Inukai, Y. Ikegami, T. Awata, and S. Katayama. 2006. LKB1, an upstream AMPK kinase, regulates glucose and lipid metabolism in cultured liver and muscle cells. Biochem. Biophys. Res. Commun. 351: 595-601. (Pubitemid 44708851)
91. Hou, X., S. Xu, K. A. Maitland-Toolan, K. Sato, B. Jiang, Y. Ido, F. Lan, K. Walsh, M. Wierzbicki, T. J. Verbeuren, et al. 2008. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem. 283: 20015-20026.
92. Yoneda M, Y. Guo, H. Ono, Y. Nakatsu, J. Zhang, X. Cui, M. Iwashita, S. Kumamoto, Y. Tsuchiya, H. Sakoda, et al. 2010. Decreased SIRT1 expression and LKB1 phosphorylation occur with long-term high-fat diet feeding, in addition to AMPK phosphorylation impairment in the early phase. Obes. Res. Clin. Pract. 4: e201-e207.
93. Purushotham, A., T. T. Schug, Q. Xu, S. Surapureddi, X. Guo, and X. Li. 2009. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9: 327-338.
94. Fulco, M., and V. Sartorelli. 2008. Comparing and contrasting the roles of AMPK and SIRT1 in metabolic tissues. Cell Cycle. 7: 3669-3679.
95. Shimano, H., J. D. Horton, R. E. Hammer, I. Shimomura, M. S. Brown, and J. L. Goldstein. 1996. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J. Clin. Invest. 98: 1575-1584. (Pubitemid 26327867)
96. Li, Y., S. Xu, M. M. Mihaylova, B. Zheng, X. Hou, B. Jiang, O. Park, Z. Luo, E. Lefai, J. Y. Shyy, et al. 2011. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 13: 376-388.
97. Um, J. H., S. J. Park, H. Kang, S. Yang, M. Foretz, M. W. McBurney, M. K. Kim, B. Viollet, and J. H. Chung. 2010. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 59: 554-563.
98. Song, Z., I. Deaciuc, Z. Zhou, M. Song, T. Chen, D. Hill, and C. J. McClain. 2007. Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G894-G902. (Pubitemid 47610419)
99. Yang, J., S. Maika, L. Craddock, J. A. King, and Z. M. Liu. 2008. Chronic activation of AMP-activated protein kinase-alpha1 in liver leads to decreased adiposity in mice. Biochem. Biophys. Res. Commun. 370: 248-253.
100. Ntambi, J. M., M. Miyazaki, J. P. Stoehr, H. Lan, C. M. Kendziorski, B. S. Yandell, Y. Song, P. Cohen, J. M. Friedman, and A. D. Attie. 2002. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc. Natl. Acad. Sci. USA. 99: 11482-11486. (Pubitemid 34920951)
101. Dobrzyn, P., A. Dobrzyn, M. Miyazaki, P. Cohen, E. Asilmaz, D. G. Hardie, J. M. Friedman, and J. M. Ntambi. 2004. Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc. Natl. Acad. Sci. USA. 101: 6409-6414. (Pubitemid 38585987)
102. Kim, Y. D., K. G. Park, Y. S. Lee, Y. Y. Park, D. K. Kim, B. Nedumaran, W. G. Jang, W. J. Cho, J. Ha, I. K. Lee, et al. 2008. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes. 57: 306-314.
103. Yamauchi, T., J. Kamon, Y. Minokoshi, Y. Ito, H. Waki, S. Uchida, S. Yamashita, M. Noda, S. Kita, K. Ueki, et al. 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8: 1288-1295. (Pubitemid 35373562)
104. Cool, B., B. Zinker, W. Chiou, L. Kifle, N. Cao, M. Perham, R. Dickinson, A. Adler, G. Gagne, R. Iyengar, et al. 2006. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3: 403-416. (Pubitemid 43811782)
105. Rauth, G., O. Poschke, E. Fink, M. Eulitz, S. Tippmer, M. Kellerer, H. U. Haring, P. Nawratil, M. Haasemann, W. Jahnen-Dechent, et al. 1992. The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur. J. Biochem. 204: 523-529.
106. Mathews, S. T., S. Rakhade, X. Zhou, G. C. Parker, D. V. Coscina, and G. Grunberger. 2006. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem. Biophys. Res. Commun. 350: 437-443. (Pubitemid 44498655)
107. Stefan, N., A. M. Hennige, H. Staiger, J. Machann, F. Schick, S. M. Krober, F. Machicao, A. Fritsche, and H. U. Haring. 2006. Alpha2- Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care. 29: 853-857. (Pubitemid 44115306)
108. Musso, G., R. Gambino, M. Durazzo, G. Biroli, M. Carello, E. Faga, G. Pacini, F. De Michieli, L. Rabbione, A. Premoli, et al. 2005. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology. 42: 1175-1183. (Pubitemid 43112685)
109. Sofer, E., M. Boaz, Z. Matas, M. Mashavi, and M. Shargorodsky. 2011. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism. 60: 1278-1284.
110. Park, H., V. K. Kaushik, S. Constant, M. Prentki, E. Przybytkowski, N. B. Ruderman, and A. K. Saha. 2002. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J. Biol. Chem. 277: 32571-32577. (Pubitemid 34984761)
111. Sponarova, J., K. J. Mustard, O. Horakova, P. Flachs, M. Rossmeisl, P. Brauner, K. Bardova, M. Thomason-Hughes, R. Braunerova, P. Janovska, et al. 2005. Involvement of AMP-activated protein kinase in fat depot-specific metabolic changes during starvation. FEBS Lett. 579: 6105-6110. (Pubitemid 41546255)
112. Gauthier, M. S., H. Miyoshi, S. C. Souza, J. M. Cacicedo, A. K. Saha, A. S. Greenberg, and N. B. Ruderman. 2008. AMP-activated protein kinase is activated as a consequence of lipolysis in the adipocyte: potential mechanism and physiological relevance. J. Biol. Chem. 283: 16514-16524.
113. Viollet, B., Y. Athea, R. Mounier, B. Guigas, E. Zarrinpashneh, S. Horman, L. Lantier, S. Hebrard, J. Devin-Leclerc, C. Beauloye, et al. 2009. AMPK: lessons from transgenic and knockout animals. Front. Biosci. 14: 19-44.
114. Orci, L., W. S. Cook, M. Ravazzola, M. Y. Wang, B. H. Park, R. Montesano, and R. H. Unger. 2004. Rapid transformation of white adipocytes into fat-oxidizing machines. Proc. Natl. Acad. Sci. USA. 101: 2058-2063. (Pubitemid 38229014)
115. Yin, W., J. Mu, and M. J. Birnbaum. 2003. Role of AMP-activated protein kinase in cyclic AMP-dependent lipolysis In 3T3-L1 adipocytes. J. Biol. Chem. 278: 43074-43080. (Pubitemid 37345923)
116. Corton, J. M., J. G. Gillespie, S. A. Hawley, and D. G. Hardie. 1995. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229: 558-565.
117. Dagon, Y., Y. Avraham, and E. M. Berry. 2006. AMPK activation regulates apoptosis, adipogenesis, and lipolysis by eIF2alpha in adipocytes. Biochem. Biophys. Res. Commun. 340: 43-47. (Pubitemid 41827645)
118. Daval, M., F. Diot-Dupuy, R. Bazin, I. Hainault, B. Viollet, S. Vaulont, E. Hajduch, P. Ferre, and F. Foufelle. 2005. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J. Biol. Chem. 280: 25250-25257. (Pubitemid 40934619)
119. Sullivan, J. E., K. J. Brocklehurst, A. E. Marley, F. Carey, D. Carling, and R. K. Beri. 1994. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett. 353: 33-36. (Pubitemid 24312538)
120. Djouder, N., R. D. Tuerk, M. Suter, P. Salvioni, R. F. Thali, R. Scholz, K. Vaahtomeri, Y. Auchli, H. Rechsteiner, R. A. Brunisholz, et al. 2010. PKA phosphorylates and inactivates AMPKalpha to promote efficient lipolysis. EMBO J. 29: 469-481.
121. Su, C. L., C. Sztalryd, J. A. Contreras, C. Holm, A. R. Kimmel, and C. Londos. 2003. Mutational analysis of the hormone-sensitive lipase translocation reaction in adipocytes. J. Biol. Chem. 278: 43615-43619. (Pubitemid 37345987)
122. Villena, J. A., B. Viollet, F. Andreelli, A. Kahn, S. Vaulont, and H. S. Sul. 2004. Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit. Diabetes. 53: 2242-2249. (Pubitemid 39145577)
123. Klaus, S., S. Keipert, M. Rossmeisl, and J. Kopecky. 2012. Augmenting energy expenditure by mitochondrial uncoupling: a role of AMP-activated protein kinase. Genes Nutr. 7: 369-386.
124. Matejkova, O., K. J. Mustard, J. Sponarova, P. Flachs, M. Rossmeisl, I. Miksik, M. Thomason-Hughes, D. Grahame Hardie, and J. Kopecky. 2004. Possible involvement of AMP-activated protein kinase in obesity resistance induced by respiratory uncoupling in white fat. FEBS Lett. 569: 245-248. (Pubitemid 38844626)
125. Rossmeisl, M., P. Flachs, P. Brauner, J. Sponarova, O. Matejkova, T. Prazak, J. Ruzickova, K. Bardova, O. Kuda, and J. Kopecky. 2004. Role of energy charge and AMP-activated protein kinase in adipocytes in the control of body fat stores. Int. J. Obes. Relat. Metab. Disord. 28 (Suppl. 4) : S38-S44. (Pubitemid 40143847)
126. Si, Y., H. Shi, and K. Lee. 2009. Metabolic flux analysis of mitochondrial uncoupling in 3T3-L1 adipocytes. PLoS ONE. 4: e7000.
127. Friedman, J. 2002. Fat in all the wrong places. Nature. 415: 268-269. (Pubitemid 34087534)
128. Gauthier, M. S., E. L. O'Brien, S. Bigornia, M. Mott, J. M. Cacicedo, X. J. Xu, N. Gokce, C. Apovian, and N. Ruderman. 2011. Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochem. Biophys. Res. Commun. 404: 382-387.
129. Martínez-Agustin, O., J. J. Hernandez-Morante, E. Martinez-Plata, F. Sanchez de Medina, and M. Garaulet. 2010. Differences in AMPK expression between subcutaneous and visceral adipose tissue in morbid obesity. Regul. Pept. 163: 31-36.
130. MacLaren, R. E., W. Cui, H. Lu, S. Simard, and K. Cianflone. 2010. Association of adipocyte genes with ASP expression: a microarray analysis of subcutaneous and omental adipose tissue in morbidly obese subjects. BMC Med. Genomics. 3: 3.
131. Boyle, J. G., P. J. Logan, G. C. Jones, M. Small, N. Sattar, J. M. Connell, S. J. Cleland, and I. P. Salt. 2011. AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. Diabetologia. 54: 1799-1809.
132. Minokoshi, Y., T. Alquier, N. Furukawa, Y. B. Kim, A. Lee, B. Xue, J. Mu, F. Foufelle, P. Ferre, M. J. Birnbaum, et al. 2004. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 428: 569-574. (Pubitemid 38480541)
133. López, M., R. Lage, A. K. Saha, D. Perez-Tilve, M. J. Vazquez, L. Varela, S. Sangiao-Alvarellos, S. Tovar, K. Raghay, S. Rodriguez-Cuenca, et al. 2008. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab. 7: 389-399. (Pubitemid 351618114)
134. Kahn, B. B., T. Alquier, D. Carling, and D. G. Hardie. 2005. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1: 15-25. (Pubitemid 43960587)
135. Ronnett, G. V., and S. Aja. 2008. AMP-activated protein kinase in the brain. Int J Obes (Lond). 32 (Suppl. 4) : S42-S48.
136. Xue, B., and B. B. Kahn. 2006. AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. J. Physiol. 574: 73-83. (Pubitemid 43905798)
137. Lim, C. T., B. Kola, and M. Korbonits. 2010. AMPK as a mediator of hormonal signalling. J. Mol. Endocrinol. 44: 87-97.
138. Kola, B., I. Farkas, M. Christ-Crain, G. Wittmann, F. Lolli, F. Amin, J. Harvey-White, Z. Liposits, G. Kunos, A. B. Grossman, et al. 2008. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One 3: e1797.
139. Ahima, R. S., Y. Qi, and N. S. Singhal. 2006. Adipokines that link obesity and diabetes to the hypothalamus. Prog. Brain Res. 153: 155-174. (Pubitemid 44107415)
140. Lage, R., C. Dieguez, A. Vidal-Puig, and M. Lopez. 2008. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol. Med. 14: 539-549.
141. Hardie, D. G. 2008. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int. J. Obes. (Lond.) 32 (Suppl 4) : S7-S12.
142. Zhang, B. B., G. Zhou, and C. Li. 2009. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 9: 407-416.
143. Lowell, B. B., and G. I. Shulman. 2005. Mitochondrial dysfunction and type 2 diabetes. Science. 307: 384-387. (Pubitemid 40139974)
144. Cantó, C., L. Q. Jiang, A. S. Deshmukh, C. Mataki, A. Coste, M. Lagouge, J. R. Zierath, and J. Auwerx. 2010. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab. 11: 213-219.
145. McGee, S. L., and M. Hargreaves. 2010. AMPK-mediated regulation of transcription in skeletal muscle. Clin. Sci. (Lond.). 118: 507-518.
146. Kus, V., T. Prazak, P. Brauner, M. Hensler, O. Kuda, P. Flachs, P. Janovska, D. Medrikova, M. Rossmeisl, Z. Jilkova, et al. 2008. Induction of muscle thermogenesis by high-fat diet in mice: association with obesity-resistance. Am. J. Physiol. Endocrinol. Metab. 295: E356-E367.
147. Minokoshi, Y., Y. B. Kim, O. D. Peroni, L. G. Fryer, C. Muller, D. Carling, and B. B. Kahn. 2002. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 415: 339-343. (Pubitemid 34087557)
148. Karagounis, L. G., and J. A. Hawley. 2009. The 5′ adenosine monophosphate-activated protein kinase: regulating the ebb and flow of cellular energetics. Int. J. Biochem. Cell Biol. 41: 2360-2363.
149. Pehmøller, C., J. T. Treebak, J. B. Birk, S. Chen, C. Mackintosh, D. G. Hardie, E. A. Richter, and J. F. Wojtaszewski. 2009. Genetic disruption of AMPK signaling abolishes both contraction- and insulin-stimulated TBC1D1 phosphorylation and 14-3-3 binding in mouse skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 297: E665-E675.
150. Holmes, B. F., E. J. Kurth-Kraczek, and W. W. Winder. 1999. Chronic activation of 5 ' -AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J. Appl. Physiol. 87: 1990-1995.
151. Jørgensen, S. B., J. F. Wojtaszewski, B. Viollet, F. Andreelli, J. B. Birk, Y. Hellsten, P. Schjerling, S. Vaulont, P. D. Neufer, E. A. Richter, et al. 2005. Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle. FASEB J. 19: 1146-1148. (Pubitemid 40946446)
152. Wright, D. C., P. C. Geiger, J. O. Holloszy, and D. H. Han. 2005. Contraction- and hypoxia-stimulated glucose transport is mediated by a Ca2+-dependent mechanism in slow-twitch rat soleus muscle. Am. J. Physiol. Endocrinol. Metab. 288: E1062-E1066. (Pubitemid 40726791)
153. Barnes, B. R., S. Marklund, T. L. Steiler, M. Walter, G. Hjalm, V. Amarger, M. Mahlapuu, Y. Leng, C. Johansson, D. Galuska, et al. 2004. The 5′-AMP-activated protein kinase gamma3 isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle. J. Biol. Chem. 279: 38441-38447. (Pubitemid 39295995)
154. Lehto, M., X. Huang, E. M. Davis, M. M. Le Beau, E. Laurila, K. F. Eriksson, G. I. Bell, and L. Groop. 1995. Human hexokinase II gene: exon-intron organization, mutation screening in NIDDM, and its relationship to muscle hexokinase activity. Diabetologia. 38: 1466-1474.
155. Jäger, S., C. Handschin, J. St-Pierre, and B. M. Spiegelman. 2007. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl. Acad. Sci. USA. 104: 12017-12022. (Pubitemid 47185622)
156. Wojtaszewski, J. F., S. B. Jorgensen, Y. Hellsten, D. G. Hardie, and E. A. Richter. 2002. Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. Diabetes. 51: 284-292. (Pubitemid 34764782)
157. Sriwijitkamol, A., D. K. Coletta, E. Wajcberg, G. B. Balbontin, S. M. Reyna, J. Barrientes, P. A. Eagan, C. P. Jenkinson, E. Cersosimo, R. A. DeFronzo, et al. 2007. Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a timecourse and dose-response study. Diabetes. 56: 836-848. (Pubitemid 46348486)
158. Steinberg, G. R., A. C. Smith, B. J. Van Denderen, Z. Chen, S. Murthy, D. J. Campbell, G. J. Heigenhauser, D. J. Dyck, and B. E. Kemp. 2004. AMP-activated protein kinase is not down-regulated in human skeletal muscle of obese females. J. Clin. Endocrinol. Metab. 89: 4575-4580. (Pubitemid 39244472)
159. Jocken, J. W., C. Roepstorff, G. H. Goossens, P. van der Baan, M. van Baak, W. H. Saris, B. Kiens, and E. E. Blaak. 2008. Hormone-sensitive lipase serine phosphorylation and glycerol exchange across skeletal muscle in lean and obese subjects: effect of beta-adrenergic stimulation. Diabetes. 57: 1834-1841.
160. Vendelbo, M. H., B. F. Clasen, J. T. Treebak, L. Moller, T. Krusenstjerna-Hafstrom, M. Madsen, T. S. Nielsen, H. Stodkilde-Jorgensen, S. B. Pedersen, J. O. Jorgensen, et al. 2012. Insulin resistance after a 72 hour fast is associated with impaired AS160 phosphorylation and accumulation of lipid and glycogen in human skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 302: E190-E200.
161. Musi, N., M. F. Hirshman, M. Arad, Y. Xing, N. Fujii, J. Pomerleau, F. Ahmad, C. I. Berul, J. G. Seidman, R. Tian, et al. 2005. Functional role of AMP-activated protein kinase in the heart during exercise. FEBS Lett. 579: 2045-2050. (Pubitemid 40469668)
162. Tian, R., N. Musi, J. D'Agostino, M. F. Hirshman, and L. J. Goodyear. 2001. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation. 104: 1664-1669. (Pubitemid 32947531)
163. Li, H. L., R. Yin, D. Chen, D. Liu, D. Wang, Q. Yang, and Y. G. Dong. 2007. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy. J. Cell. Biochem. 100: 1086-1099. (Pubitemid 46480392)
164. Li, J., D. L. Coven, E. J. Miller, X. Hu, M. E. Young, D. Carling, A. J. Sinusas, and L. H. Young. 2006. Activation of AMPK alpha- and gamma-isoform complexes in the intact ischemic rat heart. Am. J. Physiol. Heart Circ. Physiol. 291: H1927-H1934. (Pubitemid 44497701)
165. Zhang, J., D. J. Duncker, X. Ya, Y. Zhang, T. Pavek, H. Wei, H. Merkle, K. Ugurbil, A. H. From, and R. J. Bache. 1995. Effect of left ventricular hypertrophy secondary to chronic pressure overload on transmural myocardial 2-deoxyglucose uptake. A 31P NMR spectroscopic study. Circulation. 92: 1274-1283.
166. Nuutila, P., M. Maki, H. Laine, M. J. Knuuti, U. Ruotsalainen, M. Luotolahti, M. Haaparanta, O. Solin, A. Jula, V. A. Koivisto, et al.1995. Insulin action on heart and skeletal muscle glucose uptake in essential hypertension. J. Clin. Invest. 96: 1003-1009.
167. Arad, M., D. W. Benson, A. R. Perez-Atayde, W. J. McKenna, E. A. Sparks, R. J. Kanter, K. McGarry, J. G. Seidman, and C. E. Seidman. 2002. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J. Clin. Invest. 109: 357-362. (Pubitemid 34141809)
168. Kim, A. S., E. J. Miller, T. M. Wright, J. Li, D. Qi, K. Atsina, V. Zaha, K. Sakamoto, and L. H. Young. 2011. A small molecule AMPK activator protects the heart against ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 51: 24-32.
169. Russell 3rd, R. R., J. Li, D. L. Coven, M. Pypaert, C. Zechner, M. Palmeri, F. J. Giordano, J. Mu, M. J. Birnbaum, and L. H. Young. 2004. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J. Clin. Invest. 114: 495-503. (Pubitemid 39572099)
170. Russell 3rd, R. R., R. Bergeron, G. I. Shulman, and L. H. Young. 1999. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am. J. Physiol. 277: H643-H649. (Pubitemid 29415978)
171. Kolwicz, S. C., Jr., and R. Tian. 2011. Glucose metabolism and cardiac hypertrophy. Cardiovasc. Res. 90: 194-201.
172. Beauloye, C., L. Bertrand, S. Horman, and L. Hue. 2011. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc. Res. 90: 224-233.
173. Calvert, J. W., S. Gundewar, S. Jha, J. J. Greer, W. H. Bestermann, R. Tian, and D. J. Lefer. 2008. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes. 57: 696-705.
174. Nagata, D., A. Kiyosue, M. Takahashi, H. Satonaka, K. Tanaka, M. Sata, T. Nagano, R. Nagai, and Y. Hirata. 2009. A new constitutively active mutant of AMP-activated protein kinase inhibits anoxia-induced apoptosis of vascular endothelial cell. Hypertens. Res. 32: 133-139.
175. Yin, M., I. C. van der Horst, J. P. van Melle, C. Qian, W. H. van Gilst, H. H. Sillje, and R. A. de Boer. 2011. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am. J. Physiol. Heart Circ. Physiol. 301: H459-H468.
176. Benes, J., L. Kazdova, Z. Drahota, J. Houstek, D. Medrikova, J. Kopecky, N. Kovarova, M. Vrbacky, D. Sedmera, H. Strnad, et al. 2011. Effect of metformin therapy on cardiac function and survival in a volume-overload model of heart failure in rats. Clin. Sci. (Lond.). 121: 29-41.
177. Wong, G. W., S. A. Krawczyk, C. Kitidis-Mitrokostas, G. Ge, E. Spooner, C. Hug, R. Gimeno, and H. F. Lodish. 2009. Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin. FASEB J. 23: 241-258.
178. Zheng, Q., Y. Yuan, W. Yi, W. B. Lau, Y. Wang, X. Wang, Y. Sun, B. L. Lopez, T. A. Christopher, J. M. Peterson, et al. 2011. C1q/TNF-related proteins, a family of novel adipokines, induce vascular relaxation through the adiponectin receptor-1/AMPK/eNOS/nitric oxide signaling pathway. Arterioscler. Thromb. Vasc. Biol. 31: 2616-2623.
179. Kambara, T., K. Ohashi, R. Shibata, Y. Ogura, S. Maruyama, T. Enomoto, Y. Uemura, Y. Shimizu, D. Yuasa, K. Matsuo, et al. 2012. CTRP9 protein protects against myocardial injury following ischemia-reperfusion through AMP-activated protein kinase (AMPK)-dependent mechanism. J. Biol. Chem. 287: 18965-18973.
180. Gundewar, S., J. W. Calvert, S. Jha, I. Toedt-Pingel, S. Y. Ji, D. Nunez, A. Ramachandran, M. Anaya-Cisneros, R. Tian, and D. J. Lefer. 2009. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ. Res. 104: 403-411.
181. Sasaki, H., H. Asanuma, M. Fujita, H. Takahama, M. Wakeno, S. Ito, A. Ogai, M. Asakura, J. Kim, T. Minamino, et al. 2009. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation. 119: 2568-2577.
182. Bai, A., A. G. Ma, M. Yong, C. R. Weiss, Y. Ma, Q. Guan, C. N. Bernstein, and Z. Peng. 2010. AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem. Pharmacol. 80: 1708-1717.
183. Nath, N., S. Giri, R. Prasad, M. L. Salem, A. K. Singh, and I. Singh. 2005. 5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J. Immunol. 175: 566-574. (Pubitemid 40884363)
184. Zhao, X., J. W. Zmijewski, E. Lorne, G. Liu, Y. J. Park, Y. Tsuruta, and E. Abraham. 2008. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 295: L497-L504.
185. Akbar, D. H. 2003. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Endocrine. 20: 215-218. (Pubitemid 36571021)
186. Fidan, E., H. Onder Ersoz, M. Yilmaz, H. Yilmaz, M. Kocak, C. Karahan, and C. Erem. 2011. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol. 48: 297-302.
187. Ashcroft, F. M. 2005. ATP-sensitive potassium channelopathies: focus on insulin secretion. J. Clin. Invest. 115: 2047-2058. (Pubitemid 41134141)
188. Olefsky, J. M., and C. K. Glass. 2010. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72: 219-246.
189. Schenk, S., M. Saberi, and J. M. Olefsky. 2008. Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 118: 2992-3002.
190. Sag, D., D. Carling, R. D. Stout, and J. Suttles. 2008. Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 181: 8633-8641.
191. Mihaylova, M. M., and R. J. Shaw. 2011. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13: 1016-1023.
192. Kohlstedt, K., C. Trouvain, D. Namgaladze, and I. Fleming. 2011. Adipocyte-derived lipids increase angiotensin-converting enzyme (ACE) expression and modulate macrophage phenotype. Basic Res. Cardiol. 106: 205-215.
193. Rocha, V. Z., and P. Libby. 2009. Obesity, inflammation, and atherosclerosis. Nat. Rev. Cardiol. 6: 399-409.
194. Yvan-Charvet, L., N. Wang, and A. R. Tall. 2010. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler. Thromb. Vasc. Biol. 30: 139-143.
195. Li, D., D. Wang, Y. Wang, W. Ling, X. Feng, and M. Xia. 2010. Adenosine monophosphate-activated protein kinase induces cholesterol efflux from macrophage-derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice. J. Biol. Chem. 285: 33499-33509.
196. Rekhter, M. D., and D. Gordon. 1995. Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques. Am. J. Pathol. 147: 668-677.
197. Koenig, W., and N. Khuseyinova. 2007. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler. Thromb. Vasc. Biol. 27: 15-26. (Pubitemid 46360377)
198. Hardie, D. G. 2011. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 25: 1895-1908.
199. Ishii, N., T. Matsumura, H. Kinoshita, H. Motoshima, K. Kojima, A. Tsutsumi, S. Kawasaki, M. Yano, T. Senokuchi, T. Asano, et al. 2009. Activation of AMP-activated protein kinase suppresses oxidized low-density lipoprotein-induced macrophage proliferation. J. Biol. Chem. 284: 34561-34569.
200. Carlier, M. F., and D. Pantaloni. 2007. Control of actin assembly dynamics in cell motility. J. Biol. Chem. 282: 23005-23009. (Pubitemid 47311896)
201. Kanellis, J., R. K. Kandane, D. Etemadmoghadam, S. A. Fraser, P. F. Mount, V. Levidiotis, B. E. Kemp, and D. A. Power. 2006. Activators of the energy sensing kinase AMPK inhibit random cell movement and chemotaxis in U937 cells. Immunol. Cell Biol. 84: 6-12.
202. Ozcan, U., Q. Cao, E. Yilmaz, A. H. Lee, N. N. Iwakoshi, E. Ozdelen, G. Tuncman, C. Gorgun, L. H. Glimcher, and G. S. Hotamisligil. 2004. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 306: 457-461. (Pubitemid 39372439)
203. Erbay, E., V. R. Babaev, J. R. Mayers, L. Makowski, K. N. Charles, M. E. Snitow, S. Fazio, M. M. Wiest, S. M. Watkins, M. F. Linton, et al. 2009. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat. Med. 15: 1383-1391.
204. Napoli, C. 2003. Oxidation of LDL, atherogenesis, and apoptosis. Ann. N. Y. Acad. Sci. 1010: 698-709. (Pubitemid 38265068)
205. Artwohl, M., W. F. Graier, M. Roden, M. Bischof, A. Freudenthaler, W. Waldhausl, and S. M. Baumgartner-Parzer. 2003. Diabetic LDL triggers apoptosis in vascular endothelial cells. Diabetes. 52: 1240-1247. (Pubitemid 36523363)
206. Dong, Y., M. Zhang, B. Liang, Z. Xie, Z. Zhao, S. Asfa, H. C. Choi, and M. H. Zou. 2010. Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation. 121: 792-803.
207. Dong, Y., M. Zhang, S. Wang, B. Liang, Z. Zhao, C. Liu, M. Wu, H. C. Choi, T. J. Lyons, and M. H. Zou. 2010. Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo. Diabetes. 59: 1386-1396.
208. Fernández-Sánchez, A., E. Madrigal-Santillan, M. Bautista, J. Esquivel-Soto, A. Morales-Gonzalez, C. Esquivel-Chirino, I. Durante-Montiel, G. Sanchez-Rivera, C. Valadez-Vega, and J. A. Morales-Gonzalez. 2011. Inflammation, oxidative stress, and obesity. Int. J. Mol. Sci. 12: 3117-3132.
209. Cave, A. C., A. C. Brewer, A. Narayanapanicker, R. Ray, D. J. Grieve, S. Walker, and A. M. Shah. 2006. NADPH oxidases in cardiovascular health and disease. Antioxid. Redox Signal. 8: 691-728. (Pubitemid 44043102)
210. Ewart, M. A., C. F. Kohlhaas, and I. P. Salt. 2008. Inhibition of tumor necrosis factor alpha-stimulated monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinase. Arterioscler. Thromb. Vasc. Biol. 28: 2255-2257.
211. Wang, S., J. Xu, P. Song, B. Viollet, and M. H. Zou. 2009. In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I. Diabetes. 58: 1893-1901.
212. Kukidome, D., T. Nishikawa, K. Sonoda, K. Imoto, K. Fujisawa, M. Yano, H. Motoshima, T. Taguchi, T. Matsumura, and E. Araki. 2006. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes. 55: 120-127. (Pubitemid 43343306)
213. Xie, Z., J. Zhang, J. Wu, B. Viollet, and M. H. Zou. 2008. Upregulation of mitochondrial uncoupling protein-2 by the AMP-activated protein kinase in endothelial cells attenuates oxidative stress in diabetes. Diabetes. 57: 3222-3230.
214. Ceolotto, G., A. Gallo, I. Papparella, L. Franco, E. Murphy, E. Iori, E. Pagnin, G. P. Fadini, M. Albiero, A. Semplicini, et al. 2007. Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 27: 2627-2633. (Pubitemid 350158915)
215. Alba, G., R. El Bekay, M. Alvarez-Maqueda, P. Chacon, A. Vega, J. Monteseirin, C. Santa Maria, E. Pintado, F. J. Bedoya, R. Bartrons, et al. 2004. Stimulators of AMP-activated protein kinase inhibit the respiratory burst in human neutrophils. FEBS Lett. 573: 219-225. (Pubitemid 39141061)
216. Salminen, A., J. M. Hyttinen, and K. Kaarniranta. 2011. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J. Mol. Med. (Berl.) 89: 667-676.
217. Yang, S. R., J. Wright, M. Bauter, K. Seweryniak, A. Kode, and I. Rahman. 2007. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. Am. J. Physiol. Lung Cell. Mol. Physiol. 292: L567-L576.
218. Yang, Z., B. B. Kahn, H. Shi, and B. Z. Xue. 2010. Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J. Biol. Chem. 285: 19051-19059.
219. Schug, T. T., Q. Xu, H. Gao, A. Peres-da-Silva, D. W. Draper, M. B. Fessler, A. Purushotham, and X. Li. 2010. Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol. Cell. Biol. 30: 4712-4721.
220. Alvarez-Guardia, D., X. Palomer, T. Coll, M. M. Davidson, T. O. Chan, A. M. Feldman, J. C. Laguna, and M. Vazquez-Carrera. 2010. The p65 subunit of NF-kappaB binds to PGC-1alpha, linking inflammation and metabolic disturbances in cardiac cells. Cardiovasc. Res. 87: 449-458.
221. Kim, H. J., K. G. Park, E. K. Yoo, Y. H. Kim, Y. N. Kim, H. S. Kim, H. T. Kim, J. Y. Park, K. U. Lee, W. G. Jang, et al. 2007. Effects of PGC-1alpha on TNF-alpha-induced MCP-1 and VCAM-1 expression and NF-kappaB activation in human aortic smooth muscle and endothelial cells. Antioxid. Redox Signal. 9: 301-307.
222. Winder, W. W., and D. G. Hardie. 1999. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol. 277: E1-E10. (Pubitemid 29356721)
223. Hawley, S. A., J. Boudeau, J. L. Reid, K. J. Mustard, L. Udd, T. P. Makela, D. R. Alessi, and D. G. Hardie. 2003. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2: 28.
224. Davies, M. J., J. T. Judd, D. J. Baer, B. A. Clevidence, D. R. Paul, A. J. Edwards, S. A. Wiseman, R. A. Muesing, and S. C. Chen. 2003. Black tea consumption reduces total and LDL cholesterol in mildly hypercholesterolemic adults. J. Nutr. 133: 3298S-3302S. (Pubitemid 37222259)
225. Sanders, M. J., Z. S. Ali, B. D. Hegarty, R. Heath, M. A. Snowden, and D. Carling. 2007. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J. Biol. Chem. 282: 32539-32548. (Pubitemid 350159309)
226. Boudeau, J., J. W. Scott, N. Resta, M. Deak, A. Kieloch, D. Komander, D. G. Hardie, A. R. Prescott, D. M. van Aalten, and D. R. Alessi. 2004. Analysis of the LKB1-STRAD-MO25 complex. J. Cell Sci. 117: 6365-6375. (Pubitemid 40214563)
227. Xiao, B., R. Heath, P. Saiu, F. C. Leiper, P. Leone, C. Jing, P. A. Walker, L. Haire, J. F. Eccleston, C. T. Davis, et al. 2007. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature. 449: 496-500. (Pubitemid 47509548)
228. Suwa, M., H. Nakano, and S. Kumagai. 2003. Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles. J. Appl. Physiol. 95: 960-968. (Pubitemid 37033988)
229. Lochhead, P. A., I. P. Salt, K. S. Walker, D. G. Hardie, and C. Sutherland. 2000. 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes. 49: 896-903. (Pubitemid 30349410)
230. Lee, Y. S., W. S. Kim, K. H. Kim, M. J. Yoon, H. J. Cho, Y. Shen, J. M. Ye, C. H. Lee, W. K. Oh, C. T. Kim, et al. 2006. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 55: 2256-2264. (Pubitemid 44743622)
231. Ahn, J., H. Lee, S. Kim, J. Park, and T. Ha. 2008. The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem. Biophys. Res. Commun. 373: 545-549.
232. Suchankova, G., L. E. Nelson, Z. Gerhart-Hines, M. Kelly, M. S. Gauthier, A. K. Saha, Y. Ido, P. Puigserver, and N. B. Ruderman. 2009. Concurrent regulation of AMP-activated protein kinase and SIRT1 in mammalian cells. Biochem. Biophys. Res. Commun. 378: 836-841.
233. Fryer, L. G., A. Parbu-Patel, and D. Carling. 2002. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277: 25226-25232. (Pubitemid 34951829)
234. Hawley, S. A., A. E. Gadalla, G. S. Olsen, and D. G. Hardie. 2002. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 51: 2420-2425. (Pubitemid 34827390)
235. Baur, J. A., K. J. Pearson, N. L. Price, H. A. Jamieson, C. Lerin, A. Kalra, V. V. Prabhu, J. S. Allard, G. Lopez-Lluch, K. Lewis, et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 444: 337-342. (Pubitemid 44764104)
236. Hawley, S. A., F. A. Ross, C. Chevtzoff, K. A. Green, A. Evans, S. Fogarty, M. C. Towler, L. J. Brown, O. A. Ogunbayo, A. M. Evans, et al. 2010. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 11: 554-565.
237. Xie, Z., Y. Dong, R. Scholz, D. Neumann, and M. H. Zou. 2008. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation. 117: 952-962. (Pubitemid 351272593)
238. Jin, H. E., S. S. Hong, M. K. Choi, H. J. Maeng, D. D. Kim, S. J. Chung, and C. K. Shim. 2009. Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis. Pharm. Res. 26: 549-559.
239. Shu, Y., S. A. Sheardown, C. Brown, R. P. Owen, S. Zhang, R. A. Castro, A. G. Ianculescu, L. Yue, J. C. Lo, E. G. Burchard, et al. 2007. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117: 1422-1431. (Pubitemid 46718430)
240. El-Mir, M. Y., V. Nogueira, E. Fontaine, N. Averet, M. Rigoulet, and X. Leverve. 2000. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275: 223-228. (Pubitemid 30038975)
241. Owen, M. R., E. Doran, and A. P. Halestrap. 2000. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348: 607-614. (Pubitemid 30410251)
242. Shaw, R. J., K. A. Lamia, D. Vasquez, S. H. Koo, N. Bardeesy, R. A. Depinho, M. Montminy, and L. C. Cantley. 2005. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 310: 1642-1646. (Pubitemid 41780780)
243. Guigas, B., L. Bertrand, N. Taleux, M. Foretz, N. Wiernsperger, D. Vertommen, F. Andreelli, B. Viollet, and L. Hue. 2006. 5-Aminoimidazole-4- carboxamide-1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation. Diabetes. 55: 865-874. (Pubitemid 44100158)
244. Spiegelman, B. M. 1998. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47: 507-514. (Pubitemid 28160438)
245. Srivastava, R. A. 2009. Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver X receptor agonists. Eur. J. Pharmacol. 607: 258-263.
246. Srivastava, R. A. 2011. Evaluation of anti-atherosclerotic activities of PPAR-alpha, PPAR-gamma, and LXR agonists in hyperlipidemic atherosclerosis- susceptible F(1)B hamsters. Atherosclerosis. 214: 86-93.
247. Saha, A. K., P. R. Avilucea, J. M. Ye, M. M. Assifi, E. W. Kraegen, and N. B. Ruderman. 2004. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem. Biophys. Res. Commun. 314: 580-585. (Pubitemid 38084758)
248. Schimmack, G., R. A. Defronzo, and N. Musi. 2006. AMP-activated protein kinase: Role in metabolism and therapeutic implications. Diabetes Obes. Metab. 8: 591-602. (Pubitemid 44515556)
249. Bays, H., L. Mandarino, and R. A. DeFronzo. 2004. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin. Endocrinol. Metab. 89: 463-478. (Pubitemid 38269844)
250. Kadowaki, T., T. Yamauchi, N. Kubota, K. Hara, and K. Ueki. 2007. Adiponectin and adiponectin receptors in obesity-linked insulin resistance. Novartis Found. Symp. 286: 164-176; discussion 176-182, 200-203.
251. Mootha, V. K., C. M. Lindgren, K. F. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. Puigserver, E. Carlsson, M. Ridderstrale, E. Laurila, et al. 2003. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34: 267-273. (Pubitemid 36792858)
252. Zhang, F., D. Dey, R. Branstrom, L. Forsberg, M. Lu, Q. Zhang, and A. Sjoholm. 2009. BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner. Am. J. Physiol. Cell Physiol. 296: C346-C354.
253. Chen, Z., P. A. Vigueira, K. T. Chambers, A. M. Hall, M. S. Mitra, N. Qi, W. G. McDonald, J. R. Colca, R. F. Kletzien, and B. N. Finck. 2012. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor gamma-sparing thiazolidinedione. J. Biol. Chem. 287: 23537-23548.
254. Cederroth, C. R., M. Vinciguerra, A. Gjinovci, F. Kuhne, M. Klein, M. Cederroth, D. Caille, M. Suter, D. Neumann, R. W. James, et al. 2008. Dietary phytoestrogens activate AMP-activated protein kinase with improvement in lipid and glucose metabolism. Diabetes. 57: 1176-1185.
255. Collins, Q. F., H. Y. Liu, J. Pi, Z. Liu, M. J. Quon, and W. Cao. 2007. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5′-AMP-activated protein kinase. J. Biol. Chem. 282: 30143-30149. (Pubitemid 350035266)
256. Bhatia, I. S., and R. Ullah. 1962. Metabolism of polyphenols in the tea leaf. Nature. 193: 658-659.
257. Maron, D. J., G. P. Lu, N. S. Cai, Z. G. Wu, Y. H. Li, H. Chen, J. Q. Zhu, X. J. Jin, B. C. Wouters, and J. Zhao. 2003. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. Arch. Intern. Med. 163: 1448-1453. (Pubitemid 36758917)
258. Koo, S. I., and S. K. Noh. 2007. Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect. J. Nutr. Biochem. 18: 179-183. (Pubitemid 46216812)
259. Singh, D. K., S. Banerjee, and T. D. Porter. 2009. Green and black tea extracts inhibit HMG-CoA reductase and activate AMP kinase to decrease cholesterol synthesis in hepatoma cells. J. Nutr. Biochem. 20: 816-822.
260. Lan, F., J. M. Cacicedo, N. Ruderman, and Y. Ido. 2008. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J. Biol. Chem. 283: 27628-27635.
261. Dasgupta, B., and J. Milbrandt. 2007. Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. USA. 104: 7217-7222. (Pubitemid 47186035)
262. Hwang, S. L., B. K. Yang, J. Y. Lee, J. H. Kim, B. D. Kim, K. H. Suh, D. Y. Kim, M. S. Kim, H. Song, B. S. Park, et al. 2008. Isodihydrocapsiate stimulates plasma glucose uptake by activation of AMP-activated protein kinase. Biochem. Biophys. Res. Commun. 371: 289-293.
263. Li, H. B., Y. K. Ge, X. X. Zheng, and L. Zhang. 2008. Salidroside stimulated glucose uptake in skeletal muscle cells by activating AMP-activated protein kinase. Eur. J. Pharmacol. 588: 165-169.
264. López-Lázaro, M. 2008. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol. Nutr. Food Res. 52 (Suppl. 1) : S103-S127.
265. Pan, W., H. Yang, C. Cao, X. Song, B. Wallin, R. Kivlin, S. Lu, G. Hu, W. Di, and Y. Wan. 2008. AMPK mediates curcumin-induced cell death in CaOV3 ovarian cancer cells. Oncol. Rep. 20: 1553-1559.
266. Kanitkar, M., K. Gokhale, S. Galande, and R. R. Bhonde. 2008. Novel role of curcumin in the prevention of cytokine-induced islet death in vitro and diabetogenesis in vivo. Br. J. Pharmacol. 155: 702-713.
267. Fujiwara, H., M. Hosokawa, X. Zhou, S. Fujimoto, K. Fukuda, K. Toyoda, Y. Nishi, Y. Fujita, K. Yamada, Y. Yamada, et al. 2008. Curcumin inhibits glucose
268. Gruzman, A., O. Shamni, M. Ben Yakir, D. Sandovski, A. Elgart, E. Alpert, G. Cohen, A. Hoffman, Y. Katzhendler, E. Cerasi, et al. 2008. Novel D-xylose derivatives stimulate muscle glucose uptake by activating AMP-activated protein kinase alpha. J. Med. Chem. 51: 8096-8108.
269. Turner, N., J. Y. Li, A. Gosby, S. W. To, Z. Cheng, H. Miyoshi, M. M. Taketo, G. J. Cooney, E. W. Kraegen, D. E. James, et al. 2008. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 57: 1414-1418.
270. Yin, J., R. Hu, M. Chen, J. Tang, F. Li, Y. Yang, and J. Chen. 2002. Effects of berberine on glucose metabolism in vitro. Metabolism. 51: 1439-1443.
271. Jeong, H. W., K. C. Hsu, J. W. Lee, M. Ham, J. Y. Huh, H. J. Shin, W. S. Kim, and J. B. Kim. 2009. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am. J. Physiol. Endocrinol. Metab. 296: E955-E964.
272. Park, K. G., A. K. Min, E. H. Koh, H. S. Kim, M. O. Kim, H. S. Park, Y. D. Kim, T. S. Yoon, B. K. Jang, J. S. Hwang, et al. 2008. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology. 48: 1477-1486.
273. Shen, Q. W., M. J. Zhu, J. Tong, J. Ren, and M. Du. 2007. Ca2+/calmodulin-dependent protein kinase kinase is involved in AMPactivated protein kinase activation by alpha-lipoic acid in C2C12 myotubes. Am. J. Physiol. Cell Physiol. 293: C1395-C1403. (Pubitemid 47556748)
274. Clark, H., D. Carling, and D. Saggerson. 2004. Covalent activation of heart AMP-activated protein kinase in response to physiological concentrations of long-chain fatty acids. Eur. J. Biochem. 271: 2215-2224. (Pubitemid 38747990)
275. de Lange, P., P. Farina, M. Moreno, M. Ragni, A. Lombardi, E. Silvestri, L. Burrone, A. Lanni, and F. Goglia. 2006. Sequential changes in the signal transduction responses of skeletal muscle following food deprivation. FASEB J. 20: 2579-2581.
276. Fediuc, S., M. P. Gaidhu, and R. B. Ceddia. 2006. Regulation of AMP-activated protein kinase and acetyl-CoA carboxylase phosphorylation by palmitate in skeletal muscle cells. J. Lipid Res. 47: 412-420. (Pubitemid 43276927)
277. Watt, M. J., G. R. Steinberg, Z. P. Chen, B. E. Kemp, and M. A. Febbraio. 2006. Fatty acids stimulate AMP-activated protein kinase and enhance fatty acid oxidation in L6 myotubes. J. Physiol. 574: 139-147. (Pubitemid 43905803)
278. Bar-Tana, J., G. Rose-Kahn, and M. Srebnik. 1985. Inhibition of lipid synthesis by beta beta'-tetramethyl-substituted, C14-C22, alpha, omega-dicarboxylic acids in the rat in vivo. J. Biol. Chem. 260: 8404-8410. (Pubitemid 15249849)
279. Bar-Tana, J., S. Ben-Shoshan, J. Blum, Y. Migron, R. Hertz, J. Pill, G. Rose-Khan, and E. C. Witte. 1989. Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids. J. Med. Chem. 32: 2072-2084. (Pubitemid 19224168)
280. Za'tara, G., J. Bar-Tana, B. Kalderon, M. Suter, E. Morad, D. Samovski, D. Neumann, and R. Hertz. 2008. AMPK activation by long chain fatty acyl analogs. Biochem. Pharmacol. 76: 1263-1275.
281. Hermesh, O., B. Kalderon, and J. Bar-Tana. 1998. Mitochondria uncoupling by a long chain fatty acyl analogue. J. Biol. Chem. 273: 3937-3942.
282. Cramer, C. T., B. Goetz, K. L. Hopson, G. J. Fici, R. M. Ackermann, S. C. Brown, C. L. Bisgaier, W. G. Rajeswaran, D. C. Oniciu, and M. E. Pape. 2004. Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome. J. Lipid Res. 45: 1289-1301. (Pubitemid 38802632)
283. Pinkosky, S. L., C. T. Cramer, T. R. Hurley, C. D. Bradshaw, M. A. Spahr, R. A. K. Srivastava, and R. S. Newton. 2011. ETC-1002 regulates key pathways of lipid and carbohydrate metabolism in primary rat hepatocytes through a novel acyl-CoA synthetase-dependent AMP-activated protein kinase mechanism (Abstract 331). ATVB Scientific Session. 117.
284. Srivastava, R. A., T. R. Hurley, A. F. Brant, C. D. Bradshaw, J. C. Hanselman, C. Baker, M. Naples, K. Adeli, and R. S. Newton. 2011. A novel small molecule, ETC-1002, lowers proatherogenic lipoproteins, reduces adiposity, and improves hepatic steatosis in a hyperlipidemic hamster model (Abstract 97). ATVB Scientific Session: 55.
285. Hanselman, J. C., C. D. Bradshaw, A. F. Brant, C. T. Cramer, T. R. Hurley, S. L. Pinkosky, M. A. Spahr, J. G. Washburn, R. S. Newton, and R. A. K. Srivastava. 2011. ETC-1002 reduces circulating and hepatic triglyceride content and improves glycemic control in KKAy mice (Abstract 554). ATVB Scientific Session: 177.
286. MacDougall, D. E., L. A. DiCarlo, M. A. Milad, J. T. Vanderlugt, and R. S. Newton. 2011. ETC-1002 was safe, well tolerated and reduced LDL-C in a phase 1 multiple-dose study of subjects with mild dyslipidemia (Poster 344). ATVB Scientific Session: 121.
287. Cramer, C. T., R. A. Srivastava, J. Lutostanski, C. L. Bisgaier, and R. S. Newton. 2011. ETC-1002: a novel small molecule inhibitor of lipogenesis improves plasma lipid profile and inhibits atherosclerosis progression in LDLr-/- Mouse by a lipid-dependent and independent mechanism (Abstract 405). ATVB Scientific Session: 137.
288. Mukhtar, M. H., V. A. Payne, C. Arden, A. Harbottle, S. Khan, A. J. Lange, and L. Agius. 2008. Inhibition of glucokinase translocation by AMP-activated protein kinase is associated with phosphorylation of both GKRP and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294: R766-R774. (Pubitemid 351346952)
289. Vincent, M. F., M. D. Erion, H. E. Gruber, and G. Van den Berghe. 1996. Hypoglycaemic effect of AICAriboside in mice. Diabetologia. 39: 1148-1155. (Pubitemid 26319937)
290. Bergeron, R., R. R. Russell 3rd, L. H. Young, J. M. Ren, M. Marcucci, A. Lee, and G. I. Shulman. 1999. Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am. J. Physiol. 276: E938-E944. (Pubitemid 29249614)
291. Babraj, J. A., K. Mustard, C. Sutherland, M. C. Towler, S. Chen, K. Smith, K. Green, G. Leese, D. G. Hardie, M. J. Rennie, et al. 2009. Blunting of AICAR-induced human skeletal muscle glucose uptake in type 2 diabetes is dependent on age rather than diabetic status. Am. J. Physiol. Endocrinol. Metab. 296: E1042-E1048.
292. Lihn, A. S., S. B. Pedersen, S. Lund, and B. Richelsen. 2008. The anti-diabetic AMPK activator AICAR reduces IL-6 and IL-8 in human adipose tissue and skeletal muscle cells. Mol. Cell. Endocrinol. 292: 36-41.
293. Göransson, O., A. McBride, S. A. Hawley, F. A. Ross, N. Shpiro, M. Foretz, B. Viollet, D. G. Hardie, and K. Sakamoto. 2007. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J. Biol. Chem. 282: 32549-32560. (Pubitemid 350159310)
294. Treebak, J. T., J. B. Birk, B. F. Hansen, G. S. Olsen, and J. F. Wojtaszewski. 2009. A-769662 activates AMPK beta1-containing complexes but induces glucose uptake through a PI3-kinase-dependent pathway in mouse skeletal muscle. Am. J. Physiol. Cell Physiol. 297: C1041-C1052.
295. Zhou, G., I. K. Sebhat, and B. B. Zhang. 2009. AMPK activators-potential therapeutics for metabolic and other diseases. Acta Physiol. (Oxf.). 196: 175-190.
296. Pang, T., Z. S. Zhang, M. Gu, B. Y. Qiu, L. F. Yu, P. R. Cao, W. Shao, M. B. Su, J. Y. Li, F. J. Nan, et al. 2008. Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J. Biol. Chem. 283: 16051-16060.
297. Oh, S., S. J. Kim, J. H. Hwang, H. Y. Lee, M. J. Ryu, J. Park, Y. S. Jo, Y. K. Kim, C. H. Lee, K. R. Kweon, et al. 2010. Antidiabetic and antiobesity effects of Ampkinone (6f), a novel small molecule activator of AMP-activated protein kinase. J. Med. Chem. 53: 7405-7413.
298. Goodyear, L. J. 2008. The exercise pill - too good to be true? N. Engl. J. Med. 359: 1842-1844.
299. Fabianowska-Majewska, K., J. A. Duley, and H. A. Simmonds. 1994. Effects of novel anti-viral adenosine analogues on the activity of S- adenosylhomocysteine hydrolase from human liver. Biochem. Pharmacol. 48: 897-903. (Pubitemid 24285167)
300. Charton, J., S. Girault-Mizzi, M. A. Debreu-Fontaine, F. Foufelle, I. Hainault, J. G. Bizot-Espiard, D. H. Caignard, and C. Sergheraert. 2006. Synthesis and biological evaluation of benzimidazole derivatives as potent AMP-activated protein kinase activators. Bioorg. Med. Chem. 14: 4490-4518. (Pubitemid 43728675)
301. Chen, Y., K. Zhou, R. Wang, Y. Liu, Y. D. Kwak, T. Ma, R. C. Thompson, Y. Zhao, L. Smith, L. Gasparini, et al. 2009. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc. Natl. Acad. Sci. USA. 106: 3907-3912.
302. Becker, M. L., L. E. Visser, R. H. van Schaik, A. Hofman, A. G. Uitterlinden, and B. H. Stricker. 2009. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes. 58: 745-749.
303. Scott, J. W., B. J. van Denderen, S. B. Jorgensen, J. E. Honeyman, G. R. Steinberg, J. S. Oakhill, T. J. Iseli, A. Koay, P. R. Gooley, D. Stapleton, et al. 2008. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem. Biol. 15: 1220-1230.